PILOT--LEUKEMIA/LYMPHOMA AND BONE MARROW TRANSPLANTATION

$0P30FY2002CANIH

University Of Michigan At Ann Arbor, Ann Arbor MI

Investigators

Linked publications & trials

Paper 39713566 Paper 39693340 Paper 39585895 Paper 39574876 Paper 39574605 Paper 39565098 Paper 39563831 Paper 39515327 Paper 39509603 Paper 39499573 Paper 39487735 Paper 39485242 Paper 39483899 Paper 39480488 Paper 39470729 Paper 39462976 Paper 39438135 Paper 39419964 Paper 39386734 Paper 39351871 Paper 39349971 Paper 39323220 Paper 39311858 Paper 39276348 Paper 39251788 Paper 39208685 Paper 39182611 Paper 39154783 Paper 39126652 Paper 39117603 Paper 39103355 Paper 39073801 Paper 39059369 Paper 39044017 Paper 39036962 Paper 39024552 Paper 39020220 Paper 39018356 Paper 39008790 Paper 39005728 Paper 38992135 Paper 38979312 Paper 38977883 Paper 38973591 Paper 38968937 Paper 38958646 Paper 38937199 Paper 38919034 Paper 38915566 Paper 38915368 Paper 38914800 Paper 38899679 Paper 38888796 Paper 38888340 Paper 38883705 Paper 38871762 Paper 38821085 Paper 38818307 Paper 38814732 Paper 38810179 Paper 38787530 Paper 38782906 Paper 38781019 Paper 38773085 Paper 38749397 Paper 38746407 Paper 38742457 Paper 38717905 Paper 38687642 Paper 38669678 Paper 38656991 Paper 38645231 Paper 38617233 Paper 38585737 Paper 38585734 Paper 38574315 Paper 38568856 Paper 38567994 Paper 38562800 Paper 38562691 Paper 38551819 Paper 38533538 Paper 38533459 Paper 38530059 Paper 38527936 Paper 38517480 Paper 38516891 Paper 38513119 Paper 38502228 Paper 38492861 Paper 38489266 Paper 38464282 Paper 38464251 Paper 38457204 Paper 38446990 Paper 38437666 Paper 38423050 Paper 38409226 Paper 38405837 Paper 38405832

Abstract

The Leukemia/Lymphoma-BMT (LL-BMT) Program is an interdisciplinary program with 37 members from nine departments with over $3.5 million in annual direct research support. The chief scientific aims of the Program are: to devise novel treatments for leukemia, lymphoma and related hematologic disorders using immunotherapeutic approaches with or without concurrent stem cell transplant; to understand the immunobiology of allogeneic BMT in order to reduce its toxicity and increase its; and to understand hematopoietic stem cell biology with the ultimate goal of stem cell gene modification for therapeutic purposes. This program was recently organized to integrate more fully research activities related to clinical therapies of malignant hematologic diseases. This integration is exemplified by numerous intra-programmatic conferences, tumor boards and clinical research projects incorporating multiple disciplines.

View original record on NIH RePORTER →